Adenomyosis and IVF: What It Means for Fertility Treatment

Medically reviewed on 23 August 2026 - Dr. Senai Aksoy
Woman seated on a sofa holding her lower abdomen

Key Takeaways

Observational studies associate adenomyosis with less favourable fertility outcomes in some patients, but it does not make pregnancy impossible. IVF planning depends on symptoms, imaging, age, ovarian reserve and previous transfers; current evidence does not support routine hormonal suppression before frozen embryo transfer for every patient.

Key evidence: SOGC Guideline No. 437 — diagnosis and management of adenomyosis Pados et al. 2023 — adenomyosis and infertility review González-Comadran 2025 — GnRH agonists before embryo transfer

Adenomyosis and fertility: what do we know?

Adenomyosis is often found during an assessment for painful periods, heavy bleeding or difficulty conceiving. It means that glands and supporting tissue similar to the endometrium—the lining of the uterus—are present within the uterine muscle, or myometrium.

For fertility treatment, the important question is not simply whether adenomyosis appears on a scan. What matters is whether it is likely to affect the uterine environment or embryo-transfer plan, and whether treatment before transfer offers enough benefit to justify the delay and side effects.

Dr Aksoy’s approach

Adenomyosis on an ultrasound or MRI report does not mean that the uterus cannot carry a pregnancy. I avoid applying one protocol to everyone. Mild adenomyosis without symptoms does not, on its own, justify delaying transfer. If disease is clearly diffuse, the uterus is enlarged, or implantation has repeatedly failed without another explanation, I may discuss freezing all embryos and, in selected cases, temporary GnRH agonist suppression. Current research does not show a routine benefit from suppression for every patient. I also avoid surgery within the uterine muscle as a routine step because it may weaken the uterine wall in a future pregnancy.

What is adenomyosis?

Adenomyosis involves endometrial-type glands and stroma within the muscle of the uterus. The surrounding muscle may thicken and the uterus may become enlarged. Some people have no symptoms; others experience painful periods, heavy bleeding, pelvic discomfort or pressure.

SOGC Guideline No. 437 describes two broad patterns:

The distinction matters, but neither label determines fertility treatment by itself.

How may adenomyosis affect fertility?

Adenomyosis does not make pregnancy impossible. Reviews including Pados and colleagues (2023) describe several possible pathways, although their relative importance differs between patients:

  1. Endometrial receptivity: local inflammation and altered signalling may make the uterine environment less favourable for implantation.
  2. Uterine contractions: changes near the junction between the endometrium and myometrium may affect normal uterine contractions.
  3. Local inflammatory and oxidative changes: these changes may influence the environment around implantation, but the precise mechanisms remain under study.
  4. Pregnancy loss: observational studies report a higher miscarriage rate in some groups with adenomyosis. These findings cannot predict one patient’s absolute risk.

Age, embryo chromosomal status, coexisting endometriosis or fibroids, and how adenomyosis was diagnosed can all influence study results.

How is adenomyosis diagnosed?

Diagnosis usually begins with imaging rather than surgery.

Indirect ultrasound features alone are not conclusive. MRI findings such as junctional-zone changes may support the diagnosis, but no single measurement should decide every case. The SOGC guideline recommends interpreting imaging alongside symptoms and treatment history.

IVF planning: is treatment needed before embryo transfer?

Not every patient with adenomyosis needs pretreatment. Decisions should consider symptoms, the appearance and size of the uterus, age, ovarian reserve, previous IVF outcomes and the implications of delaying transfer.

Freeze-all and delayed transfer

In selected situations, embryos may be frozen rather than transferred immediately after ovarian stimulation. This separates egg collection from embryo transfer and allows time for reassessment or treatment.

That can be useful, but it is not a default requirement for every patient with adenomyosis.

GnRH agonist suppression

GnRH agonists temporarily reduce hormonal activity and may ease symptoms or reduce uterine volume. Pretreatment before transfer is sometimes discussed for selected patients, but there is no single standard duration.

This is not, however, a routine evidence-based step for everyone. The 2025 systematic review and meta-analysis by González-Comadran and colleagues, based on eight retrospective studies, found no improvement in reproductive outcomes from GnRH agonist pretreatment before frozen embryo transfer.

The decision should therefore weigh symptoms and imaging against side effects, age and the delay before transfer.

Surgery has a limited role

Diffuse adenomyosis has no clear surgical plane separating it from healthy uterine muscle. Extensive excision can leave a substantial scar and may increase the risk of uterine rupture in a future pregnancy.

Surgery is therefore not routine before IVF. In the specific context of recurrent implantation failure, the 2026 ASRM opinion also notes that evidence for surgery before embryo transfer remains limited. Surgery may be considered only in exceptional, carefully selected cases of focal disease after specialist review. Our separate guide explains the indications and limits of surgery for adenomyosis.

Questions that can guide an individual plan

Clinical situationFeatures to reviewUseful discussion point
Mild or asymptomatic adenomyosisIncidental imaging finding; little change in uterine sizeWould treatment add enough benefit to justify delaying transfer?
More extensive or symptomatic diseaseEnlarged uterus, pain or several imaging featuresWhat are the possible benefits and limitations of delaying transfer or using hormonal suppression?
Unexplained implantation failurePrevious transfers without implantationHave embryo-related, cavity-related and other factors been reviewed before attributing failure to adenomyosis?
Focal disease affecting the cavityA defined lesion that may alter the cavityIs multidisciplinary review appropriate, and could the uncertain potential benefits of surgery outweigh uterine-wall risks?

Video by Dr Senai Aksoy

Adenomyosis and IVF — Dr Senai Aksoy

This video was recorded in French. English subtitles are available in the YouTube player settings.

What should you take away?

An adenomyosis diagnosis does not mean pregnancy is impossible or that IVF will fail. It means that the scan needs to be interpreted in context.

The most useful plan considers symptoms, imaging, age, ovarian reserve and previous transfers together. The aim is to avoid unnecessary treatment and a transfer at the wrong time.

FAQ

Can I become pregnant with adenomyosis?

Yes. Pregnancy can occur naturally or with IVF. The effect varies with age, embryo factors, symptoms, the extent of disease and other fertility conditions.

Does adenomyosis always reduce IVF success?

No. Observational research finds less favourable outcomes in some groups, but mild or incidental adenomyosis does not have the same clinical significance for every patient. No scan can predict an individual IVF result on its own.

How long does GnRH agonist pretreatment take?

There is no single standard duration. Its benefit before frozen embryo transfer has not been established for all patients, so side effects and the impact of delaying transfer must also be considered. The available evidence is summarised in the 2025 systematic review and meta-analysis.

Is ultrasound enough to diagnose adenomyosis?

Specialist transvaginal ultrasound can support the diagnosis in many cases when recognised imaging features are interpreted together. Indirect features alone are not conclusive. MRI can help when findings are uncertain, detailed mapping is required or fibroids complicate the picture.

Not routinely. Surgery may weaken the uterine wall, and its comparative effect on reproductive and live-birth outcomes remains uncertain because the available studies are heterogeneous. It is reserved for highly selected focal cases after specialist assessment.

What records should I bring to a fertility consultation?

Bring previous ultrasound and MRI reports, details of earlier IVF cycles and embryo transfers, hormone and ovarian-reserve results, and a brief note of any pain or bleeding symptoms.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.